Pharma / Biotech

340B Covered Entities Facing Deadlines for New Manufacturer Requirements

With October deadlines looming, hospitals and health systems that participate in the 340B drug pricing program are scrambling to respond to a flurry of new audit demands from drug manufacturers, as well as manufacturer limitations on the number of contract pharmacies that these covered entities are allowed to use under 340B.

Source link

Related posts

SMART SENSE ANTISEPTIC SKIN CLEANSER (Chlorhexidine Gluconate 4%) Liquid [Xttrium Laboratories, Inc.]


Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma.


A phase I pharmacokinetic and pharmacodynamic study of GTI-2040 in combination with gemcitabine in patients with solid tumors.


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy